A review summarizing predictors of the primary response to biologic treatment, including anti–tumor necrosis factor (TNF) agents, vedolizumab, and ustekinumab concluded that currently, we do not have any biomarkers that can be used as a predictor of response to biologic treatment in IBD (6). Here, TNF is linked to inflammatory bowel disease.